Related Experiment Videos
A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature
Kabir A Khan1, Robert S Kerbel2
1Biological Sciences, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.
Abstract:
In this issue of Cancer Cell, Seaman et al. demonstrate that antibody drug conjugates (ADCs) against CD276 expressed by tumor cells and tumor vasculature have promising anti-tumor activity while showing little toxicity. Importantly, these agents have the potential to target both angiogenic vessels and non-angiogenic vessels co-opted by tumor cells.
Insights
Antibody drug conjugates targeting CD276 show potent anti-tumor effects. These novel agents effectively target tumor vasculature and cells with minimal toxicity, offering a promising new cancer therapy.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Biology
Background:
- CD276 is a cell surface protein expressed on tumor cells and vasculature.
- Targeting tumor-associated antigens is a key strategy in cancer therapy.
- Antibody drug conjugates (ADCs) offer targeted delivery of cytotoxic agents.
Purpose of the Study:
- To evaluate the anti-tumor activity and toxicity of ADCs targeting CD276.
- To investigate the potential of CD276-targeted ADCs in different types of tumor vasculature.
Main Methods:
- Development and characterization of ADCs against CD276.
- In vitro and in vivo studies to assess anti-tumor efficacy.
- Toxicity profiling of the developed ADCs.
Main Results:
- CD276-targeted ADCs demonstrated significant anti-tumor activity.
- These agents showed efficacy against both angiogenic and non-angiogenic tumor vessels.
- Minimal toxicity was observed in preclinical models.
Conclusions:
- ADCs targeting CD276 are a promising therapeutic strategy for cancer treatment.
- The ability to target diverse tumor vasculature enhances their potential clinical utility.
- Further investigation into CD276-targeted ADCs is warranted.